British multinational pharmaceutical company GlaxoSmithKline (NYSE: GSK) declared in its last quarterly earnings call that the company’s integration and restructuring programs are on track, and sales are benefiting from recent new product introductions and most products recently acquired.So much so, that the company says it will meet its guidance for 2015… Read More
Analyst Articles
The sector is already well on its way toward generating clean power. Read More
The flight to safety means higher REIT prices and dividend income. Read More
The flight to safety means higher REIT prices and dividend income. Read More
In a rising-rate environment, management holds the key to outperformance. Read More
Water assets around the world are about to become more valuable. Read More
The precipitous decline in shares of so-called Yield Companies confirms our suspicions of their dubious quality. Read More
Nuveen’s top asset manager, Robert C. Doll, predicts more volatility and lower returns as he says the “easy money” has been made. Read More
Nuveen’s top asset manager, Robert C. Doll, predicts more volatility and lower returns as he says the “easy money” has been made. Read More
Why our top stocks will do well under a variety of scenarios. Read More